- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05034276
Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder
July 18, 2023 updated by: Eric Garland, University of Utah
This is a Phase 1 trial that aims to establish the safety of MORE-VR, as well as to collect feasibility, usability, and engagement data, for patients receiving medications for opioid use disorder (mOUD).
Study Overview
Study Type
Interventional
Enrollment (Actual)
34
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Center on Mindfulness and Integrative Health Intervention Development
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 18 or older
- DSM-5 opioid use disorder diagnosis
- treated with medications for opioid use disorder (MOUD)
Exclusion Criteria:
- Mindfulness intervention experience (MBSR, MBRP)
- Active psychosis or high risk of suicidality
- Cognitive impairment (per self-report or report by clinician)
- Unwilling or unable to remain in MOUD treatment for duration of study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MORE-VR
Mindfulness-Oriented Recovery Enhancement deployed over virtual reality.
|
Mindfulness-Oriented Recovery Enhancement therapy delivered over virtual reality.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events and/or Serious Adverse Events
Time Frame: Baseline through week 8
|
Number of participants who reported adverse events and serious adverse events.
|
Baseline through week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Engagement
Time Frame: Baseline through week 8
|
Net Promoter Score (NPS) is a engagement and satisfaction measurement taken from asking participants how likely they were to recommend the MORE-VR intervention to others on a scale of 0-10.
Net Promoter Score (NPS) is calculated by subtracting the percentage of customers who answer the NPS question with a 6 or lower (known as 'detractors') from the percentage of customers who answer with a 9 or 10 (known as 'promoters').
The summary Net Promoter Score is reflected as a percentage.
|
Baseline through week 8
|
Numeric Rating Scale of State Craving
Time Frame: Baseline through week 8
|
Craving measured on a 0 to 10 numeric rating scale, with 0 indicating no craving and 10 indicating extreme craving.
|
Baseline through week 8
|
Numeric Rating Scale of State Positive Affect
Time Frame: Baseline through week 8
|
Positive affect measured on a 0 to 10 numeric rating scale, with 0 indicating no positive affect and 10 indicating very high positive affect.
|
Baseline through week 8
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Desire for Drugs
Time Frame: Baseline, week 8
|
Desires for Drugs Questionnaire
|
Baseline, week 8
|
Trait Positive and Negative Affect
Time Frame: Baseline, week 8
|
Positive and Negative Affect Schedule
|
Baseline, week 8
|
Coping Self-efficacy
Time Frame: Baseline, week 8
|
Drug Taking Confidence Questionnaire
|
Baseline, week 8
|
Cue-elicited Heart Rate
Time Frame: Baseline through week 8
|
Heart rate during cue exposure minus baseline heart rate
|
Baseline through week 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 4, 2021
Primary Completion (Actual)
April 1, 2022
Study Completion (Actual)
July 22, 2022
Study Registration Dates
First Submitted
September 1, 2021
First Submitted That Met QC Criteria
September 1, 2021
First Posted (Actual)
September 5, 2021
Study Record Updates
Last Update Posted (Actual)
July 20, 2023
Last Update Submitted That Met QC Criteria
July 18, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB_00141495
- R44DA053848 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid-use Disorder
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorder | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Aurora Health CareUniversity of Chicago; University of California, Santa Cruz; Rogers Behavioral...RecruitingSubstance Use | Methamphetamine-dependence | Opioid Use | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Use | Methamphetamine AbuseUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorders | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Vanderbilt University Medical CenterCompletedOpioid Use | Opioid-use DisorderUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Albert Einstein College of MedicineNational Institute on Drug Abuse (NIDA); Pfizer; National Institutes of Health...Active, not recruitingTobacco Use Disorder | Opioid-use DisorderUnited States
-
Indiana UniversityCompletedOpioid Use | Opioid-use DisorderUnited States
-
University of ZurichCompletedOpioid Use, Unspecified With Other Opioid-induced DisorderSwitzerland
-
Virginia Commonwealth UniversityNational Institute on Drug Abuse (NIDA)CompletedOpioid-use Disorder | Cocaine Use Disorder | Healthy Controls | Marijuana Use DisorderUnited States
-
New York State Psychiatric InstituteColumbia University; Weill Medical College of Cornell University; National Institute... and other collaboratorsActive, not recruitingOpioid Use | Opioid Court Model | Medication to Treat Opioid Use DisorderUnited States
Clinical Trials on MORE-VR
-
National Institute of General Medical Sciences...Completed
-
Shanghai Mental Health CenterNanjing XR-Oasis Technology Co., Ltd.RecruitingBipolar Disorder | Interventional Study | VRChina
-
Catholic University of the Sacred HeartFondazione PoliambulanzaRecruiting
-
Indiana UniversityAmerican Heart AssociationCompletedHeart Failure | Cognitive DysfunctionUnited States
-
Children's Hospital Medical Center, CincinnatiCompleted
-
University of Maryland, BaltimoreNot yet recruitingPain | Virtual Reality | Temporomandibular Disorder | PlaceboUnited States
-
Cornell UniversityRecruitingPain ThresholdUnited States
-
National Institutes of Health Clinical Center (CC)Not yet recruitingNeoplasm | CaregiversUnited States
-
Medical University of LodzNational Center for Research and Development, Poland; Senopi AGRecruiting
-
Azienda Ospedaliero-Universitaria di ParmaMinistry of Health, ItalyRecruitingStroke | Hemiplegia | HemiparesisItaly